We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

INmune Bio Inc (INMB) USD0.001

Sell:$12.35 Buy:$12.50 Change: $0.85 (7.28%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.85 (7.28%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.85 (7.28%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

INmune Bio, Inc. is a clinical-stage biotechnology pharmaceutical company. The Company is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient’s disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). It has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer’s and treatment resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.

Contact details

225 Ne Mizner Blvd, Suite 640
United States
+1 (858) 9643720

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$213.02 million
Shares in issue:
18.02 million
United States
US dollar

Key personnel

  • Raymond Tesi
    President, Chief Executive Officer, Director
  • David Moss
    Chief Financial Officer
  • Mark Lowdell
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.